ATRECA INC A Stock Price, News & Analysis

Atreca, Inc. (NASDAQ: BCEL) has appointed Dr. Stephen Gould as its new Chief Scientific Officer, bringing over 15 years of experience from Genentech. Dr. Gould's expertise in developing antibody-based therapeutics is expected to enhance Atreca's innovative discovery platform, which identifies tumor-targeting antibodies from the human immune response. The company is currently advancing its preclinical pipeline, including the lead candidate ATRC-101, which is in a Phase 1b study for solid tumors. The appointment aims to strengthen the company’s position in immunotherapy.

Atreca, Inc. (NASDAQ: BCEL) announced a corporate reorganization aimed at extending its cash runway through 2023, which includes a workforce reduction of over 25%. The company remains focused on developing its oncology pipeline, specifically ATRC-101 and ATRC-301, with plans to present updated clinical trial data in the second half of 2022. Despite the operational streamlining, Atreca aims to continue leveraging its proprietary discovery platform for future drug development.

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, announced its upcoming presentations at major investor conferences. The schedule includes:

• H.C. Wainwright Global Investment Conference: May 25, 2022, at 8:30 am EDT
• Cowen’s 3rd Annual Oncology IO Next Summit: June 2, 2022, at 2:00 pm EDT
• Jefferies Healthcare Conference: June 9, 2022, at 9:00 am EDT

Live webcasts will be available on their website, with replays accessible for 30 days post-event.

Atreca, Inc. (NASDAQ: BCEL) reported its Q1 2022 financial results, showing a net loss of $24.9 million, or $0.65 per share. The company's cash and cash equivalents totaled $125.8 million. Noteworthy developments include progress in clinical trials, with the ATRC-101 Phase 1b trial enrolling 55 participants, and the announcement of ATRC-301 as its next clinical candidate targeting EphA2. Atreca also established a licensing agreement with Zymeworks to use their technology for developing novel antibody-drug conjugates (ADCs), marking significant milestones toward advancing its oncology pipeline.

Atreca (NASDAQ: BCEL) announced the publication of preclinical data regarding its lead product candidate, ATRC-101, in the Proceedings of the National Academy of Sciences (PNAS). The study demonstrates that ATRC-101 activates innate immune cells and prompts tumor destruction through a novel mechanism. Key findings include tumor-selective binding, enhanced antitumor activity when combined with doxorubicin, and evidence of immune memory in murine models. Atreca is currently enrolling patients in a Phase 1b study for ATRC-101 targeting multiple solid tumors, with further clinical data expected later this year.

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced its participation in two upcoming virtual investor conferences. The Needham 21st Annual Healthcare Conference will take place on April 13, 2022, at 2:15 p.m. EDT, while the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference is set for April 14, 2022, at 12:00 p.m. EDT, focusing on Gamma Delta T-cells and Informative B-cells. Live audio webcasts can be accessed via Atreca's website, with archived replays available for 30 days post-event.

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), has entered into a licensing agreement with Zymeworks to utilize its ZymeLink™ technology for developing novel antibody-drug conjugates (ADCs). The company declared ATRC-301, an ADC targeting EphA2, as its next clinical candidate. Atreca plans to submit an Investigational New Drug (IND) application for ATRC-301 in the second half of 2023. Additionally, ongoing preclinical studies demonstrate strong anti-tumor activity across other oncology programs derived from its unique discovery platform.

Atreca, a clinical-stage biotechnology company focused on innovative therapeutics based on the human immune response, will host a virtual R&D Day on April 5, 2022, at 4:15 p.m. EDT. The event will showcase preclinical pipeline programs in oncology, featuring presentations by key executives, including CEO John Orwin and Chief Strategy Officer Tito Serafini. Following the presentation, a live Q&A session will be held. Interested participants can register for the event on Atreca's website.

Atreca's lead candidate, ATRC-101, is currently undergoing a Phase 1b study in solid tumors.

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will have President and CEO John Orwin participate in a panel discussion at Cowen’s 42nd Annual Healthcare Conference from March 7-9, 2022. The panel will focus on Novel Oncology Targets and is scheduled for March 7, 2022, from 12:50 to 1:50 p.m. EST. A live audio webcast will be available on their website, with a replay accessible for 90 days post-event. Atreca specializes in developing antibody-based immunotherapeutics and is currently enrolling patients for a Phase 1b study of its lead product candidate, ATRC-101.